Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia
- 1Department of Clinical Laboratory, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, and People’s Hospital of Henan University
- 2Department of Hematology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, and People’s Hospital of Henan University
Abstract
Purpose This study aimed to evaluate the impact of azacitidine (AZA) combined with venetoclax (VEN) compared to AZA monotherapy on systemic inflammatory markers and the overall response rate (ORR) in elderly patients with newly-diagnosed acute myeloid leukemia (AML) who were unfit for intensive chemotherapy. Methods A retrospective cohort study included 205 patients (≥ 60 years) treated between January 2021 and June 2022. Patients received either AZA alone (n = 93) or AZA plus VEN (n = 112). Serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were measured at baseline and after three treatment cycles. ORR was assessed using International Working Group criteria. Results The combination therapy group showed significantly greater reductions in inflammatory markers (CRP, IL-6, TNF-α; all P < 0.001) and improved hematological recovery compared to monotherapy. ORR was higher with combination therapy (73.21% vs. 46.24%, P < 0.001). Baseline TNF-α > 70 pg/mL was independently associated with lower ORR (OR 0.589, P = 0.016). The incidence of adverse events did not differ significantly between groups. Conclusion AZA plus VEN was associated with significantly greater reductions in systemic inflammation and improved treatment responses compared to AZA monotherapy in elderly AML patients, without a significant increase in severe toxicity. These findings suggest that the combination regimen may be a promising first-line option for this population; however, prospective randomized trials are warranted to confirm these observations.
Related
- Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy
- Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia
- Response to Venetoclax and Azacitidine in Induction-Refractory Adult Acute Myeloid Leukemia with UBTF Tandem Duplication and Associated Aberrant Splicing: A Case Report
- Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study
- Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML
BibTeX
@article{liu2026effects,
title = {{Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia}},
author = {Hui-Fang Liu and Cheng Lian and Xian-Guang Zhu},
journal = {BMC Geriatrics},
year = {2026},
month = jul,
doi = {10.1186/s12877-026-08036-y},
url = {https://doi.org/10.1186/s12877-026-08036-y},
note = {CC BY},
}
RIS
TY - JOUR
TI - Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia
AU - Hui-Fang Liu
AU - Cheng Lian
AU - Xian-Guang Zhu
PY - 2026
DA - 2026/07/01
JO - BMC Geriatrics
DO - 10.1186/s12877-026-08036-y
UR - https://doi.org/10.1186/s12877-026-08036-y
AB - Purpose This study aimed to evaluate the impact of azacitidine (AZA) combined with venetoclax (VEN) compared to AZA monotherapy on systemic inflammatory markers and the overall response rate (ORR) in elderly patients with newly-diagnosed acute myeloid leukemia (AML) who were unfit for intensive chemotherapy. Methods A retrospective cohort study included 205 patients (≥ 60 years) treated between January 2021 and June 2022. Patients received either AZA alone (n = 93) or AZA plus VEN (n = 112). Serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were measured at baseline and after three treatment cycles. ORR was assessed using International Working Group criteria. Results The combination therapy group showed significantly greater reductions in inflammatory markers (CRP, IL-6, TNF-α; all P < 0.001) and improved hematological recovery compared to monotherapy. ORR was higher with combination therapy (73.21% vs. 46.24%, P < 0.001). Baseline TNF-α > 70 pg/mL was independently associated with lower ORR (OR 0.589, P = 0.016). The incidence of adverse events did not differ significantly between groups. Conclusion AZA plus VEN was associated with significantly greater reductions in systemic inflammation and improved treatment responses compared to AZA monotherapy in elderly AML patients, without a significant increase in severe toxicity. These findings suggest that the combination regimen may be a promising first-line option for this population; however, prospective randomized trials are warranted to confirm these observations.
SN - 1471-2318
ER -